NCT07688551 Superiority Trial of Aphasia-focused Rehabilitation With tDCS Stimulation
| NCT ID | NCT07688551 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | University of South Carolina |
| Condition | Aphasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2026-07-14 |
| Primary Completion | 2030-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 130 participants in total. It began in 2026-07-14 with a primary completion date of 2030-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to help us understand if adding transcranial Direct Current Stimulation (tDCS), a non-invasive brain stimulation technique, to Speech Therapy improves language recovery in people with Broca's aphasia and is more effective than Speech Therapy alone.
Eligibility Criteria
Inclusion Criteria: * Be willing and able to give informed consent. * Be willing and able to comply with study requirements. * Be between 25 and 80 years of age. * Have used English as the primary language for \> 15 years. * Have the diagnosis of aphasia due to a left hemisphere stroke, confirmed by study physician based on past clinical MRI scan or research scan. * Be greater than 6 months post-stroke. * Have Broca's aphasia diagnosed by the WAB-R (fluency score ≤ 5, auditory verbal comprehension score 4-10, repetition score 0-7.9, naming and word finding score \< 9). * Correctly name 140 or fewer items on the PNT. Exclusion Criteria: * History of brain surgery except for during the treatment of the acute stroke. * Seizures during the previous 12-months. * Compromised skin at or near electrode sites (e.g., rash, eczema, wounds, infection). * Correctly name more than 140 out of 175 items during the pre-treatment picture naming test (Philadelphia Naming Test). * Western Aphasia Battery-Revised Aphasia Quotient (WAB-R AQ) score of 25 or below. * Participants with open skull defects (e.g., greater than 1 cm) in the area underneath the anode electrode positioning or participants with metal implants or electrical stimulators. * Participants with continuous oxygen therapy which cannot be discontinued for more than 1 hour. * Any condition or situation that the PI determines would significantly interfere with the participant's ability to complete the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07688551 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 80 Years, studying Aphasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07688551 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07688551 currently recruiting?
Yes, NCT07688551 is actively recruiting participants. Contact the research team at Leonardo.Bonilha@uscmed.sc.edu for enrollment information.
Where is the NCT07688551 trial being conducted?
This trial is being conducted at Charleston, United States, Columbia, United States, Salt Lake City, United States.
Who is sponsoring the NCT07688551 clinical trial?
NCT07688551 is sponsored by University of South Carolina. The trial plans to enroll 130 participants.